Nitric Oxide Releasing Solution to Treat and Prevent Exacerbation of Mild COVID-19 Infection

SARS-CoV Infection Clinical Trial

Official title:

Double-Blinded, Placebo-Controlled Parallel, Phase II Clinical Efficacy Study Evaluating NORS To Treat and Prevent the Exacerbation of Infection in Individuals With Documented Mild COVID-19

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04443868
• Other study ID #: COVID-IND-02
• Status: Withdrawn
• Phase: Phase 2
• Start date: January 2021
• Est. completion date: July 2021

Study information

• Verified date: July 2021
• Source: Sanotize Research and Development corp.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a double-blinded, placebo-controlled parallel, phase II clinical efficacy study evaluating Nitric Oxide Nasal Irrigation (NONI) for the treatment of COVID-19 in individuals with mild COVID-19 Infection.

Description:

Up to 50 subjects will be enrolled into one of two cohorts of this study in a ratio of 1:1 (Treatment: Placebo Control). Subjects will be screened and randomized into one of two parallel cohorts. - Treatment (N = up to 25): Subjects will be enrolled and receive daily NONI treatment for 14 days with a follow-up visit on Day 28 post randomization. - Placebo (N = up to 25): Subjects will be enrolled and receive a placebo for 14 days with a follow-up visit on Day 28 post randomization.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: July 2021
• Est. primary completion date: April 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Capable of understanding and providing signed informed consent and ability to adhere to the requirements and restrictions of this protocol;
• Men and Women = 18years of age;
• Internet access and capability and willingness to use to participate in audio or audio/video engagements with medical professionals, receive texts, emails, and phone calls from study staff and have a device and reasonable cellular data or other internet access to submit daily study required information using a smart phone, tablet, laptop, or desktop computer during the study period;
• COVID-19 infection confirmed with a laboratory antigen or SARS-CoV-2 RT-PCR nasal swab;
• Specimen collected within the past 48 hours;
• Mild COVID /FLU symptoms which may include no symptoms, fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, lack of taste or smell without shortness of breath or dyspnea;
• Must be willing to use one highly effective birth control method which include:

abstinence, hormonal contraceptives (e.g. combined oral contraceptives, patch, vaginal ring, injectables, and implants); intrauterine device (IUD) or intrauterine system (IUS); vasectomy and tubal ligation or to use two forms of effective birth control methods which include: barrier methods of contraception (e.g. male condom, female condom, cervical cap, diaphragm, contraceptive sponge);

• Hormonal methods and the IUD must be in use at least 30 days prior to first Study drug administration
• Abstinence and barrier methods must be in use at least 14 days prior to Study drug administration
• Vasectomy must be completed 3 months prior to first Study drug administration; or in the alternative that a 0 sperm count will suffice.

Exclusion Criteria:

• Current tracheostomy or laryngectomy;
• Concomitant respiratory therapy such as oxygen or ventilatory support. Positive airway pressure for obstructive sleep apnea is permitted if treatment was established with good compliance at least 3 months before enrolment;
• Need for hospitalization for any reason;
• Inability to safely self-administer nasal irrigation
• Any clinical contraindications, as judged by the Qualified Medical Practitioner;
• Clinical signs indicative of moderate, severe or critical COVID severity symptoms (as defined by FDA COVID-19 Guidance Document)
• Mentally or neurologically disabled patients who are considered not fit to consent to their participation in the study;
• Lactating, pregnant or planning to become pregnant during the study period;
• Diagnosed with prior COVID-19 infection (>48 hours from the time the test is reported prior to the time of screening).

Related Conditions & MeSH terms

• Communicable Diseases
• Infection
• SARS-CoV Infection
• Severe Acute Respiratory Syndrome

Intervention

Drug:
• Nitric Oxide-Releasing Drug
Nasal Spray + Nasal Irrigation

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Sanotize Research and Development corp.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To Measure the efficacy of NONI compared to saline placebo control to shorten the duration of COVID-19 viral infectivity	Measure the SARS-CoV-2 viral load (Cycle threshold) at baseline through Day 6 between NONI and control arms.	6 Days
Secondary	To Measure the virucidal effect of NONI compared to placebo in the nasal cavity in subjects with mild COVID-19 infection	Measure the proportion of subjects reaching Ct threshold (ie: unmeasurable viral load) between NONI and control	2, 4 and 6 days
Secondary	To Measure the virucidal effect of NONI compared to placebo in the nasal cavity in subjects with mild COVID-19 infection	Measure the difference in time-to Ct threshold (ie: unmeasurable viral load) between NONI and control.	2, 4 and 6 days
Secondary	To Measure the efficacy of NONI in prevention of progression of COVID-19	Measure the proportion of subjects requiring hospitalization or ER/ED visits for COVID-19/flu-like symptoms	28 days
Secondary	To measure reduction of patient reported outcome (PRO) of clinical cold score symptoms and quality of life (QoL) in subjects with COVID-19	Measure the difference in 12-point COVID Symptom PROs score 0-3 (min 0 & max 36) and a QoL score from 0-100 (lower is worse) from baseline between NONI and control arms.	6 days
Secondary	To measure reduction of patient reported outcome (PRO) of clinical cold score symptoms and quality of life in subjects with COVID-19	Measure the difference in proportion of subjects experiencing a reduction of = 5 from baseline between NONI and control arms.	2, 4, 6, 14 and 28 days
Secondary	To measure reduction of patient reported outcome (PRO) of clinical cold score symptoms and quality of life in subjects with COVID-19	Measure the difference in proportion of subjects with reduction to a score of zero from baseline between NONI and control arms.	2, 4, 6, 14 and 28 days
Secondary	To measure the tolerance of NONI compared to saline placebo in participants with mild COVID-19 infection	Number of participants lost-to-follow-up,discontinuing study treatment or number of treatments due to intolerance	14 days
Secondary	To measure the tolerance of NONI compared to saline placebo in participants with mild COVID-19 infection	Severity and frequency of adverse events, pain, discomfort or discontinuations of treatment.	14 days